These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18199501)

  • 1. Metabolic agents in the management of diabetic coronary patients: a new era.
    Marazzi G; Volterrani M; Rosano GM
    Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic agents in the management of diabetic coronary patients: a new era.
    Celik T; Kursaklioglu H; Iyisoy A; Jata B
    Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic modulation: a new therapeutic target in treatment of heart failure.
    Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
    Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM; Vitale C; Fragasso G
    Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
    Lee L; Horowitz J; Frenneaux M
    Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
    Rizzon P; Iliceto S; Marangelli V
    Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732
    [No Abstract]   [Full Text] [Related]  

  • 9. Modulation of myocardial metabolism: an emerging therapeutic principle.
    Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL
    Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
    Marazzi G; Wajngarten M; Vitale C; Patrizi R; Pelliccia F; Gebara O; Pierri H; Ramires JA; Volterrani M; Fini M; Rosano GM
    Int J Cardiol; 2007 Aug; 120(1):79-84. PubMed ID: 17134770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metabolic approach in diabetic patients with coronary artery disease.
    Fragasso G; Salerno A; Spoladore R; Cera M; Montanaro C; Margonato A
    Curr Pharm Des; 2009; 15(8):857-62. PubMed ID: 19275650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic angina: new medical options for treatment.
    McCullough PA
    Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
    Inglis S; Stewart S
    Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effects of trimetazidine on left ventricular function and physical exercise tolerance in patients with ischemic cardiomyopathy].
    Sisakian AS; Torgomian AL; Barkhudarian AL
    Klin Med (Mosk); 2006; 84(10):55-8. PubMed ID: 17201276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic stable angina pectoris.
    Jawad E; Arora R
    Dis Mon; 2008 Sep; 54(9):671-89. PubMed ID: 18725007
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic therapy for the diabetic patients with ischaemic heart disease.
    Rosano GM; Vitale C; Volterrani M; Fini M
    Coron Artery Dis; 2005 Nov; 16 Suppl 1():S17-21. PubMed ID: 16340399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Heart disease and diabetes: from pathophysiology to therapeutic options].
    Fragasso G; Palloshi A; Bassanelli G; Steggerda R; Montano C; Margonato A
    Ital Heart J; 2004 Mar; 5 Suppl 2():4S-15S. PubMed ID: 15074772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.